| Identification | Back Directory | [Name]
TC-N 1752 | [CAS]
1211866-85-1 | [Synonyms]
TC-N 1752
TC-N 1752-d5
Nav1.7 blocker 52
TCN 1752,TC N 1752
N-[2-METHYL-3-[[4-[4-[[4-(TRIFLUOROMETHOXY)PHENYL]METHOXY]-1-PIPERIDINYL]-1,3,5-TRIAZIN-2-YL]AMINO]PHENYL]ACETAMIDE
AcetaMide, N-[2-Methyl-3-[[4-[4-[[4-(trifluoroMethoxy)phenyl]Methoxy]-1-piperidinyl]-1,3,5-triazin-2-yl]aMino]phenyl]- | [Molecular Formula]
C25H27F3N6O3 | [MOL File]
1211866-85-1.mol | [Molecular Weight]
516.52 |
| Chemical Properties | Back Directory | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble to 100 mM in DMSO and to 10 mM in 1eq. HCl | [form ]
Powder | [pka]
14.80±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
TC-N 1752 is a potent, state-dependent inhibitor of Nav1.7, which is a neuronal voltage gated sodium channel and a critical mediator of pain sensitization. | [in vivo]
TC-N 1752 (compound 52) (3-30 mg/kg; p.o.) dose-dependently shows analgesic effect in the Formalin model[1].
TC-N 1752 (3-30 mg/kg; p.o.) decreases thermal hyperalgesia produced by inflammation[3].
TC-N 1752 (5 mg/mL; 500 μL; i.v.) attenuates complete Freund’s adjuvant (CFA)-induced sensitization of C-fiber nociceptors[3]. | Animal Model: | Rats were injected intraplantar with Formalin[1] | | Dosage: | 3, 10, 20, 30 mg/kg | | Administration: | Administered p.o. 120 min prior to Formalin | | Result: | Showed analgesic efficacy starting at the dose of 3 mg/kg, with full efficacy at 20 mg/kg dose.
|
| [IC 50]
hNav1.7: 0.17 μM (IC50); hNav1.8: 0.1 μM (IC50); hNav1.3: 0.3 μM (IC50); hNav1.4: 0.4 μM (IC50); hNav1.5: 1.1 μM (IC50) | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|